Subunit-specific modulation of [(3)H]MK-801 binding to NMDA receptors mediated by dopamine receptor ligands in rodent brain

Neurochemistry International
Mattis B WigestrandS Ivar Walaas

Abstract

Dopamine D1 receptor (D1R) ligands may directly interact with the NMDA receptor (NMDAR), but detailed knowledge about this effect is lacking. Here we identify D1R ligands that directly modulate NMDARs and examine the contributions of NR2A and NR2B subunits to these interactions. Binding of the open channel blocker [(3)H]MK-801 in membrane preparations from rat- and mouse brain was used as a biochemical measure of the functional state of the NMDAR channel. We show that both D1R agonist A-68930 and dopamine receptor D2 antagonist haloperidol can decrease [(3)H]MK-801 binding with increased potency in membranes from the NR2A(-/-) mice (i.e. in membranes containing NR2B only), as compared to the inhibition obtained in wild-type membranes. Further, a wide range of D1R agonists such as A-68930, SKF-83959, SKF-83822, SKF-38393 and dihydrexidine were able to decrease [(3)H]MK-801 binding, all showing half maximal inhibitory concentrations ~20 μM, and with significant effects occurring at or above 1 μM. With membranes from D1R(-/-) mice, we demonstrate that these effects occurred through a D1R-independent mechanism. Our results demonstrate that dopamine receptor ligands can selectively influence NR2B containing NMDARs, and we characteri...Continue Reading

References

Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Jun 25, 1991·European Journal of Pharmacology·M P DeNinnoL Bednarz
Jun 12, 1990·European Journal of Pharmacology·P H Andersen, J A Jansen
Feb 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J E Huettner, B P Bean
Aug 3, 1989·European Journal of Pharmacology·J Bormann
Jul 4, 1989·European Journal of Pharmacology·T W LovenbergR B Mailman
Sep 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·E H WongL L Iversen
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·Y Y Huang, E R Kandel
Jul 1, 1994·Trends in Pharmacological Sciences·P Seeman, H H Van Tol
Dec 4, 1998·Biological Psychiatry·H Rosengarten, A J Friedhoff
Jun 18, 1999·British Journal of Pharmacology·N G CastroY Aracava
Nov 3, 2001·Science·P Greengard
Dec 6, 2002·Journal of Neurophysiology·Jorge Flores-HernándezMichael S Levine
Apr 5, 2003·Journal of Neurochemistry·Li-Qing JinEitan Friedman
Oct 14, 2003·Synapse·Sarah K LeonardRichard B Mailman
Feb 26, 2004·Proceedings of the National Academy of Sciences of the United States of America·Guojun ChenZhen Yan
May 19, 2004·Archives of Neurology·Jean-Antoine Girault, Paul Greengard
Sep 24, 2004·Progress in Neurobiology·Jeremy K Seamans, Charles R Yang
Jul 25, 2006·Cell and Tissue Research·Georg Köhr
Aug 22, 2006·Molecular Pharmacology·Changhai CuiMarco Atzori
Oct 26, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jean-Christophe CorvolDenis Hervé
Jun 16, 2007·Neuropharmacology·Jakob von EngelhardtHannah Monyer
Jun 30, 2007·Annual Review of Neuroscience·Wolfram Schultz
Oct 31, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jonathan Moss, J Paul Bolam
Jun 2, 2011·Frontiers in Systems Neuroscience·Frédéric ChavaneAmiram Grinvald
Sep 10, 2011·Frontiers in Neuroanatomy·Sven Ivar WalaasAngus Clark Nairn

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Barrel cortex

Here is the latest research on barrel cortex, a region of somatosensory and motor corticies in the brain, which are used by animals that rely on whiskers for world exploration.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here